SIGN UPLog In

Last deal

$250M

Amount

Post-IPO Equity

Stage

15.06.2023

Date

7

all rounds

$911.1M

Total amount

General

About Company
Zentalis Pharmaceuticals is developing novel small molecule therapeutics targeting fundamental biological pathways in cancer.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Zentalis, Zeno Pharmaceuticals, Zeno Pharma, Llc

founded date

01.12.2014

Number of employees

101-250

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

It has a drug discovery engine, Integrated Discovery Engine, to develop small molecule new chemical entities. Its pipeline includes two lead product candidates, ZN-c5 for advanced breast cancer and ZN-c3 for advanced solid tumors and ovarian cancer.
Contacts

location

New York, NY, USA

Phone number

Website URL

https://www.zentalis.com/

Social url